Journal: Clinical Cancer Research

Article Title: The Potential of the Gut Microbiota and Butyrate to Enhance CAR T-cell Therapy in Non-Hodgkin Lymphoma

doi: 10.1158/1078-0432.CCR-25-1676

Figure Lengend Snippet: The gut microbiota prior to CAR T-cell treatment differs between responders and nonresponders and constitutes a prognostic factor. A, PFS curves of patients classified based on high or low indices of bacterial richness, α-diversity, and evenness of the gut microbiota ( n = 57). According to maximally selected rank statistics, the cutoff points for categorization were calculated at 150, 3.487, and 0.641 for the richness, α-diversity, and evenness indices, respectively. B, Taxonomic comparison of gut microbiota families with significantly different relative abundance before CAR T-cell treatment between responders and nonresponders ( n = 57). C, Taxonomic comparison of gut microbiota genera with significantly different relative abundance before CAR T-cell treatment between responders and nonresponders ( n = 57). The analysis shows taxa with differential abundance between responders (green) and nonresponders (red) based on log 2 fold change values. Log 2 fold change was calculated as follows: log 2 (mean relative abundance in responders/mean relative abundance in nonresponders). Therefore, positive values indicate higher abundance in responders, whereas negative values indicate higher abundance in nonresponders. D, Schematic representation of fecal microbiota transplantation (FMT) validation in an A20 immunocompetent model. Mice were subjected to endogenous microbiota depletion by administering a cocktail of antibiotics for 3 days. Subsequently, FMT was performed on four alternate days. Fourteen days after the last FMT, A20 tumor cells were injected, followed by treatment with murine CD19 CAR T cells 14 days later. E, Survival curve of the experiment with A20 mice transplanted with microbiota from responder ( n = 7) and nonresponder ( n = 8) patients subsequently treated with murine CD19 CAR T cells, in comparison with A20 control mice injected with saline ( n = 9) or mock-transduced T cells ( n = 9). ASV, amplicon sequence variant; CP, cyclophosphamide.

Article Snippet: Two weeks after this, 5 × 10 5 murine aggressive lymphoma A20 cells (RRID:CVCL_1940; cat. #TIB-208, ATCC) were intravenously injected into the tail vein, and 1 × 10 6 murine CD19 CAR T cells ( ) were intravenously injected into the tail vein 14 days later.

Techniques: Comparison, Transplantation Assay, Biomarker Discovery, Injection, Control, Saline, Amplification, Sequencing, Variant Assay

Journal: STAR Protocols

Article Title: Protocol for covalent-targeted and activatable photoacoustic imaging agent for tumor imaging in mice

doi: 10.1016/j.xpro.2025.104046

Figure Lengend Snippet: Selective inhibition and labeling of NCEH1 by JS013 and NOx-JS013 (A) Gel-based ABPP results of PC3 cells treated with JS013 and NOx-JS013. (B) Gel-based ABPP results of PC3 cells treated with JW480 then JS013 and NOx-JS013. (C) Confocal fluorescence images of PC3 cells treated with NOx-JS013. (D) Confocal fluorescence images of PC3 cells treated with JS013. Scale bars represent 50 μm. (Adapted with permission from Song et al. ).

Article Snippet: PC3 (aggressive) , ATCC , #CRL-1435.

Techniques: Inhibition, Labeling, Fluorescence

Journal: STAR Protocols

Article Title: Protocol for covalent-targeted and activatable photoacoustic imaging agent for tumor imaging in mice

doi: 10.1016/j.xpro.2025.104046

Figure Lengend Snippet: In vivo tumor imaging using NOx-JS013 (A) PA images of JS013 and NOx-JS013 labeled NCEH1 in the tumor region of PC3 mouse models treated with NOx-JS013 ( p = 0.0018 from a paired t -test). (B) Unmixed signal intensities of JS013 and NOx-JS013 from the tumors in PC3 mouse models (n = 6). Data are mean ± SEM. P value were determined using unpaired t -test. ∗ p < 0.05, ∗∗ p < 0.01. (C) PA images of JS013 and NOx-JS013 labeled NCEH1 in the thigh region of PC3 mouse models treated with NOx-JS013. (D) Unmixed signal intensities of JS013 and NOx-JS013 from the thighs in PC3 mouse models (n = 6). Data are mean ± SEM. (E) PA images of JS013 and NOx-JS013-labeled NCEH1 in the tumor regions of PC3 mouse models treated with NOx-JS013; PC3 mouse models treated with JW480, then NOx-JS013; and LNCaP mouse models treated with NOx-JS013. (F) Unmixed signal intensities of JS013 and NOx-JS013 from three groups of tumor-bearing mouse models (PC3: n = 6, PC3 + JW480: n = 5, LNCaP: n = 4). Data are mean ± SEM ( p = 0.011 and 0.014, respectively, from unpaired t -test). (Adapted with permission from Song et al. ).

Article Snippet: PC3 (aggressive) , ATCC , #CRL-1435.

Techniques: In Vivo, Imaging, Labeling

Journal: STAR Protocols

Article Title: Protocol for covalent-targeted and activatable photoacoustic imaging agent for tumor imaging in mice

doi: 10.1016/j.xpro.2025.104046

Figure Lengend Snippet: In vivo tumor imaging using NOx-JS013 (A) PA images of JS013 and NOx-JS013 labeled NCEH1 in the tumor region of PC3 mouse models treated with NOx-JS013 ( p = 0.0018 from a paired t -test). (B) Unmixed signal intensities of JS013 and NOx-JS013 from the tumors in PC3 mouse models (n = 6). Data are mean ± SEM. P value were determined using unpaired t -test. ∗ p < 0.05, ∗∗ p < 0.01. (C) PA images of JS013 and NOx-JS013 labeled NCEH1 in the thigh region of PC3 mouse models treated with NOx-JS013. (D) Unmixed signal intensities of JS013 and NOx-JS013 from the thighs in PC3 mouse models (n = 6). Data are mean ± SEM. (E) PA images of JS013 and NOx-JS013-labeled NCEH1 in the tumor regions of PC3 mouse models treated with NOx-JS013; PC3 mouse models treated with JW480, then NOx-JS013; and LNCaP mouse models treated with NOx-JS013. (F) Unmixed signal intensities of JS013 and NOx-JS013 from three groups of tumor-bearing mouse models (PC3: n = 6, PC3 + JW480: n = 5, LNCaP: n = 4). Data are mean ± SEM ( p = 0.011 and 0.014, respectively, from unpaired t -test). (Adapted with permission from Song et al. ).

Article Snippet: LNCaP clone FGC (non-aggressive) , ATCC , #CRL-1740.

Techniques: In Vivo, Imaging, Labeling